This article first appeared on GuruFocus.
Novartis (NYSE:NVS), the Swiss pharmaceutical giant, absorbed a brutal setback Tuesday after del-desiran missed the primary endpoint in a pivotal myotonic-dystrophy trial. The stock plunged 10.1% to $138.51, erasing approximately CHF24 billion from the company’s market value, according to Reuters. The disappointment strikes directly at Novartis’s $12 billion acquisition of Avidity Biosciences.
Novartis’s HARBOR update showed that the roughly 150-patient study failed to deliver a statistically significant improvement over placebo in video hand-opening time. Some secondary and exploratory measures indicated clinical activity, while the safety profile remained consistent with earlier findings. Management will review the complete dataset before deciding whether the program still deserves further investment.
Novartis Crashes 13.5% After $12 Billion Deal’s Lead Drug Fails · us.finance.gurufocus
The acquisition price represents approximately 2.2 times Novartis’s latest quarterly free cash flow of $5.56 billion. Del-desiran’s failure does not destroy the entire Avidity portfolio, but it leaves the other two programs carrying far more weight. At $138.51, the stock remains 2.21% above its $135.51 GF Value, suggesting the selloff has erased optimism without yet creating an obvious valuation discount. Novartis still targets 5%6% annual sales growth through 2030, but investors now want harder evidence that the remaining pipeline can justify that promise.